Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study of PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

NCT05003141 is registered in ClinicalTrials.gov with Qilu Puget Sound Biotherapeutics (dba Sound Biologics) as lead sponsor.

NCT NCT05003141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05003141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study of PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Lead sponsor
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Phase
Phase 1
Overall status
Unknown status
Start date
November 15, 2021
Completion date
January 31, 2024
Enrollment
110 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, indolent lymphoma, malt lymphoma, mantle cell lymphoma, marginal zone lymphoma, refractory b-cell lymphoma, waldenstrom macroglobulinemia